Compare iShares MSCI Canada (TSX) (EWC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares MSCI Canada (TSX) trades at $59.18 (market cap $7.22B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: iShares MSCI Canada (TSX) is far larger — about 7.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EWC | MRVI | |
|---|---|---|
Market Cap | $7.22B | $977.37M |
Volume | 1,285,678 | 2,742,564 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $9.00 |
52-Week Low | $49.72 | $2.83 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC is trading at $59.91, up 0.77% with a bullish technical signal supported by moving averages. The stock shows neutral oscillator readings with RSI at balanced levels. Recent news highlights significant trade tensions between Canada and the US, with potential EU associate membership discussions creating both opportunities and risks for Canadian-focused investments.
The outlook remains cautiously optimistic given technical strength, but fundamental metrics are unavailable. Key risks include US-Canada trade war escalation and geopolitical uncertainties. Investors should monitor trade negotiations and economic data for directional cues on this Canada-focused equity.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
